New SARS-CoV-2 Variant Could Evade Antibodies
New SARS-CoV-2 Variant Could Evade Antibodies
A preprint casts doubt on vaccine effectiveness in light of certain mutations in the 501Y.V2 variant that emerged from South Africa.
New SARS-CoV-2 Variant Could Evade Antibodies
New SARS-CoV-2 Variant Could Evade Antibodies

A preprint casts doubt on vaccine effectiveness in light of certain mutations in the 501Y.V2 variant that emerged from South Africa.

A preprint casts doubt on vaccine effectiveness in light of certain mutations in the 501Y.V2 variant that emerged from South Africa.

vaccines
Accelerating Discovery in the Age of a Pandemic
Accelerating Discovery in the Age of a Pandemic
The Scientist Creative Services Team | Jan 22, 2021
An expert panel will present how synthetic biology accelerates the development of diagnostics, therapeutics, and the medicinal pipeline.
What’s Ahead for SARS-CoV-2 Research in 2021
What’s Ahead for SARS-CoV-2 Research in 2021
Shawna Williams | Jan 8, 2021
From new treatments to an investigation into the virus’s origins, here are some of the developments we can expect this year.
Severe Allergic Reactions to COVID-19 Vaccine Are Rare: CDC
Severe Allergic Reactions to COVID-19 Vaccine Are Rare: CDC
Lisa Winter | Jan 7, 2021
The majority of people experiencing anaphylaxis had a history of allergic reactions, a report by the agency finds.
2020 in Scientists’ Own Words
2020 in Scientists’ Own Words
Abby Olena | Dec 23, 2020
The world was rocked by the COVID-19 pandemic this year, but researchers rose to all manner of challenges.
The Many Model Systems of COVID-19
The Many Model Systems of COVID-19
Abby Olena | Nov 4, 2020
Researchers turn to familiar model animals, along with some fresh strategies, to develop countermeasures against SARS-CoV-2 and investigate the biology of infection.
Contributors
Contributors
The Scientist Staff | Nov 1, 2020
Meet some of the people featured in the November 2020 issue of The Scientist.
Infographic: How Vaccines Train Innate Immunity
Infographic: How Vaccines Train Innate Immunity
Shawna Williams | Nov 1, 2020
A recent study elucidates some of the changes that occur in the body after inoculation with a tuberculosis vaccine.
A Challenge Trial for COVID-19 Would Not Be the First of Its Kind
A Challenge Trial for COVID-19 Would Not Be the First of Its Kind
Jef Akst | Oct 8, 2020
Although scientists debate the ethics of deliberately infecting volunteers with SARS-CoV-2, plenty of consenting participants have been exposed to all sorts of pathogens in prior trials.
Scientist as Subject
Scientist as Subject
Amanda Heidt | Oct 1, 2020
In the past, it was not uncommon for researcher to test their experimental therapeutics and vaccines on themselves. Some even volunteered to be exposed to pathogen-carrying vectors.